Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 8NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Lymphoma 7Leukemia 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hodgkin Disease 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Leukemia-Lymphoma, Adult T-Cell 2Immunoblastic Lymphadenopathy 2Sezary Syndrome 1Neutropenia 1Neoplasms 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Large Granular Lymphocytic 1Leukemia, Erythroblastic, Acute 1

Interventions

Cyclosporine 2fludarabine phosphate 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1Methylprednisolone 1Methotrexate 1Cyclophosphamide 1Busulfan 1Antilymphocyte Serum 1Alemtuzumab 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Anemia, Aplastic × Alemtuzumab × Clear all
NCT00895739 2013-08-12

Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure

National Cancer Institute (NCI)

Phase 2 Unknown
50 enrolled
Classical hematology

Anemia, Aplastic, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡